United Therapeutics picked a startup over the ISS to reinvent its lung drugs in microgravity

Why $187M Changes the Calculus

Varda Space Industries closed a $187 million Series C that more than doubled its $90 million Series B from April 2024, pushing total capital to $329 million. When a startup raises that much to build orbital drug labs, the money isn't exploratory; it's industrial.

Natural Capital and Shrug Capital led the round, with Founders Fund, Peter Thiel, Khosla Ventures, Lux Capital, Caffeinated Capital, and Also Capital participating. Varda did not disclose its valuation, but the dollar figure alone resets the benchmark for space-biotech companies. No other orbital-manufacturing startup has stacked this much capital behind scaled pharmaceutical production.

CEO Will Bruey told CNBC the funding does two things: "increase cadence, meaning more flights more often, so the rate of flying," and "build out our biologics lab," which screens drug molecules on the ground before preparing formulations for flight. Three missions have returned successfully. W-4 is in orbit now, and a fifth is expected before year's end. The FAA has already granted Varda a Part 450 reentry license good for unlimited landings over five years at Australia's Koonibba Test Range, which amounts to the regulatory clearance to fly monthly.

Processing pharmaceuticals in orbit and returning them through atmosphere at Mach 25 demands spacecraft, lab infrastructure, reentry vehicles, and a flight cadence that matches pharmaceutical development timelines. Ravi Tanuku, Natural Capital's general partner and now a Varda board member, said the company sits "at the intersection of national-security need and pharmaceutical innovation." A $48 million Air Force Research Lab contract pays for the hypersonic side. The Series C pays for the pharma side.

That split matters for anyone tracking where the money flows in orbital manufacturing. Varda isn't raising $329 million to fly demonstration payloads. It's raising it to deliver what Bruey called "the world's first microgravity-enabled drug formulation," and to hire the teams who can make that repeatable.

The Mattel-Plant Pivot

Varda's production hub in El Segundo, California, shares a campus where spacecraft get built alongside the bioprocess payloads they'll carry, collapsing the distance between a drug formulation leaving a clean room and the vehicle that flies it to orbit.

Job postings describe a facility where vehicles, equipment, and materials are built, integrated, and tested under one roof, a setup that mirrors how traditional pharma companies co-locate R&D with pilot manufacturing. The company is hiring manufacturing engineers for structures, avionics, electromechanical harnessing, and payloads; process engineers; fluid systems engineers focused on pharmaceutical payloads; and ground fluids engineers supporting propulsion development. Salaries for these El Segundo roles range from roughly $120,000 to $200 000 a year, placing Varda in direct competition with established aerospace employers for experienced hardware talent.

What makes the facility notable is the convergence of disciplines it demands. A biologics formulation scientist working on protein stability in microgravity sits a few doors from a senior mission design engineer plotting reentry trajectories. Fluid systems engineers handling pharmaceutical payloads work alongside propulsion development engineers. That overlap is the point: orbital biomanufacturing isn't a satellite project with a drug experiment bolted on. It requires people who understand both the thermal and structural demands of a reentry vehicle and the sterile handling requirements of a biologic drug product.

The El Segundo campus also signals that Varda's production cadence is moving beyond one-off demonstrations. Multiple manufacturing engineer postings, each tied to a different subsystem, suggest a workforce structured around repeatable build cycles rather than a single research vehicle. For the space industry, that shift from bespoke spacecraft assembly to production-line manufacturing is the difference between an experiment and a business, and it pulls hiring pipelines away from traditional defense primes toward companies that have built high-rate production before.

Big Pharma Validates Microgravity Biomanufacturing

Varda didn't just raise $187 million in July 2025 to build a pharma lab in orbit. On May 13, 2026, it proved a major drug company would pay to use one. The El Segundo-based startup announced a collaboration with United Therapeutics, a $25-billion-market-cap public biopharma firm, to process small-molecule pulmonary disease drugs aboard Varda's W-series spacecraft and return the results on reentry capsules. Financial terms and the mission timeline remain undisclosed, but the signal is legible: a public company had contracted to manufacture physical products in space for the first time.

On Earth, sedimentation and convection currents disrupt how molecules crystallize, limiting the uniformity of drug structures. In microgravity, crystals form more slowly and with higher order, producing polymorphs that can improve bioavailability, stability, and delivery. United Therapeutics CEO Martine Rothblatt said the company was paying Varda to identify new crystal forms of its lung medicines that could have improved properties. Varda CEO Will Bruey framed it as "completing the bridge from microgravity science to patient benefit on Earth."

What makes this more than a press release is the operational architecture behind it. Varda's platform is end-to-end: launch payloads to low Earth orbit on SpaceX rideshare missions, process pharmaceuticals in microgravity aboard the W-series spacecraft, and return finished products via reentry capsules that hit the atmosphere at roughly Mach 25 before parachuting to land. The company has flown multiple craft to orbit so far, carrying both drug demonstrations and U.S. Air Force hypersonic research. Varda chief strategy officer Michael Reilly told MIT Technology Review that the company expected to launch United Therapeutics' drugs into orbit early next year.

Rothblatt, speaking at the Beyond Earth Symposium in February 2026, explained why United chose Varda over the International Space Station. She said she had considered ISS-based pharmaceutical research many times but called the station "such a logistical hassle." Varda, she said, had "routinized" the process. She did not rule out future work on commercial space stations but added that if orbital automated spacecraft could reshape molecules into novel forms, "that opens up billions of dollars in markets."

The collaboration de-risks orbital biomanufacturing as a talent category. If polymorph screening in microgravity produces viable drug candidates, the demand won't stop at one partner company. It will pull formulation scientists, orbital-process engineers, and autonomous-mission operators out of terrestrial pharma and traditional aerospace and into a workforce that treats low Earth orbit as a production floor.

Who Varda Is Hiring and Where They're Coming From

Varda's open roles tell a precise story about what building an orbital biopharma operation actually requires on the ground. Zero G Talent's board currently lists 10 Varda positions added in the past week alone: propulsion, mission design, structures integration, avionics harnessing, payload integration, and ground fluids engineering, all out of El Segundo, all at salaries that compete directly with established aerospace employers.

The pay bands make the talent war concrete. Varda's Senior Mission Design Engineer role lists $170,000 to $200,000 a year. Manufacturing Engineers in avionics and payloads range from $140,333 to $179,314. Even structures and integration manufacturing engineers start at $119,543. These aren't startup lottery-ticket offers; they're calibrated to pull experienced people out of roles at SpaceX, Northrop Grumman, Relativity Space, and JPL, where the same skills command similar bands but apply to launch vehicles and satellites rather than pharmaceutical production capsules.

Look at the role titles and you can reverse-engineer Varda's hardware dependencies. A Senior Propulsion Development Engineer working on ground fluids means Varda needs someone who understands propellant loading sequences for spacecraft that have to survive reentry and land intact. Manufacturing Engineers split across structures, avionics, payloads, and harnessing point to an operation that is integrating multiple spacecraft simultaneously, not prototyping one-off experiments. And a senior mission design engineer at the top of that salary range signals that Varda is still iterating orbital mechanics for reentry trajectories that protect temperature-sensitive biologic payloads during descent.

The talent pools overlap in ways that matter for anyone considering a move. Thermal-protection and reentry work at Varda draws from the same engineers who design heat shields at SpaceX or hypersonic vehicle thermal systems at defense contractors. Bioprocess and payload integration roles pull from the biotech manufacturing world, meaning people running GMP suites who understand cold-chain logistics and sterile processing. Autonomous navigation and mission design recruit from the satellite and launch-vehicle side, where the same skills apply but the end product is different.

What makes this migration unusual is the direction of pull. Historically, space-industry hiring flowed from defense contractors into commercial launch companies. Varda is pulling from both of those pools simultaneously while also reaching into biopharma, a sector whose engineers have traditionally had no reason to look at orbital mechanics. A manufacturing engineer with a biotech background who moves to Varda's El Segundo facility is entering a role where the production floor feeds a spacecraft not a shipping dock. That's a different career trajectory than any other orbital manufacturing company's roles offer, because Varda's end product returns to Earth as a drug, not as data or a component.

Varda vs. the Orbital-Manufacturing Pack

Varda isn't the only company chasing orbital manufacturing, but its competitors have taken paths that reveal, by contrast, exactly why Varda's hiring profile looks the way it does. The sector has split into three broad camps, each pulling from a different talent pool and each constrained by a different technical ceiling.

Redwire has built the broadest in-space manufacturing portfolio, spanning 3D printing, bioprinting, and materials processing on the ISS. The company's experience running payloads on station gives it deep institutional knowledge of microgravity hardware integration. But Redwire's business model is a services-and-components shop: it builds hardware that other companies operate, which means its workforce skews toward payload integration, flight-systems engineering, and government program management. When Redwire hires, it's often for specific mission contracts rather than a sustained production cadence. That creates a workforce that's versatile but spread thin across dozens of programs.

SpacePharma takes the opposite approach: a focused, small-satellite platform for pharma research. The company's autonomous lab-on-a-satellite design is elegant for running crystallization and biological experiments in orbit. But SpacePharma's micro-platforms don't return to Earth. Samples come back on cargo vehicles or not at all, which limits the kind of full-cycle bioprocessing that pharmaceutical companies need for production-scale work. The talent SpacePharma draws reflects that scope: small teams of microsystems engineers and pharma researchers, not the reentry-vehicle and thermal-protection specialists Varda is actively recruiting.

Axiom Space occupies the largest stage of the three, building the first commercial space station. Axiom's workforce is dominated by the infrastructure problem: life-support systems, structural analysis, station operations. Zero g talent s board shows Axiom's current Houston openings include life-support thermal engineers, structural analysis managers, and biomedical flight controllers, the core disciplines of keeping humans alive in orbit. That's a fundamentally different hiring thesis than Varda's. Axiom needs people who can build and run a habitat; Varda needs people who can build a pharmaceutical production line that survives reentry.

The distinction matters for anyone evaluating where to place their career. Redwire offers breadth and flight heritage. SpacePharma offers pharma focus at small scale. Axiom offers the chance to build a station. Varda is asking engineers to solve a problem none of those companies have fully tackled: close the loop between orbital production and terrestrial delivery. That means manufacturing engineers who understand payload integration, mission designers who can plan reentry trajectories, and thermal-protection specialists who can keep a capsule intact through reentry with a pharmaceutical payload inside. Varda's board currently lists ten open roles in El Segundo, and the split tells the story: manufacturing engineers covering structures, avionics, payloads, and ground fluids, plus one plotting reentry trajectories and a propulsion development engineer. That's not a research team. That's a production department.

The workforce moat forms because those skills don't transfer cleanly from any single existing employer. A thermal-protection engineer coming from a defense reentry program understands the physics but not the pharma cleanroom requirements. A bioprocess engineer from a terrestrial drug manufacturer understands the biology but not the vibration, radiation, and recovery constraints of orbital hardware. Varda has to hire across both domains and train at the intersection, which means the people who build that institutional knowledge become hard to replace. The Series C and the El Segundo facility give Varda the runway to do that training at scale, while competitors remain either too broad, too small, or too focused on infrastructure over production.

Space Workforce Enters Its Biotech Chapter

For decades, the space-industrial workforce built one thing: access. Rockets, satellites, and the ground infrastructure to support them. That's still most of the hiring. But Varda's $329 million in total capital, its El Segundo production facility, and the United Therapeutics agreement collectively mark a different trajectory. When a pharma company contracts orbital drug formulation that cannot be produced on Earth, the talent question flips. You no longer staff for launch. You staff for what happens between orbit and reentry, and for the biological processes running inside the capsule.

The shift from experimental to industrial biomanufacturing in microgravity demands people who can turn a crystallization process proven on Mission 5 into something repeatable at scale across Missions 10 through 50. Zero G Talent's board shows Varda added 10 roles in the past week alone, dominated by manufacturing engineers across payloads, structures, avionics, and integration, plus a Senior Mission Design Engineer at $170,000–$200,000 per year. These aren't research posts. They're production hires.

The university pipeline isn't ready

No accredited program currently grants a degree in orbital bioprocess engineering. Aerospace departments teach orbital mechanics; bioengineering departments teach downstream processing at one gravity. The overlap is a gap. Students specializing in either field emerge without the vocabulary of the other. A thermal-protection specialist who can size a heat shield for a returning capsule doesn't know what monoclonal antibody crystallization requires in transit. A bioprocess engineer who can optimize a fed-batch culture has never accounted for residual microgravity vibration affecting crystal nucleation.

Varda's hiring pattern reveals the workaround: pull experienced talent from adjacent industries and train on the job. But that approach doesn't scale. As Redwire, SpacePharma, and Axiom push their own orbital-manufacturing agendas, competition for the same cross-disciplinary talent intensifies. Universities will either introduce joint concentrations (aerospace departments embedding bioprocess modules, bioengineering departments requiring orbital-environment coursework) or firms will internalize training at growing cost.

Defense meets biotech in orbit

The convergence isn't only commercial. Nature reported that orbital biomanufacturing will have "far-reaching implications for the defense and commercial sectors in space and on Earth," specifically around supply-chain resiliency and orbital sustainability. The logic is direct: if pharmaceutical production can occur off-planet, the supply chain for critical therapeutics gains a node that terrestrial disruption, whether natural disaster, geopolitical conflict, or infrastructure failure, cannot easily reach. Defense planners care about that redundancy.

That priority accelerates the defense-biotech talent bleed. Engineers who once stabilized missile-guidance algorithms now face recruiters asking if they can instead stabilize a reentry vehicle carrying crystallized drug product. The work shares structural similarities (autonomous systems, extreme-environment reliability, hardware-software integration) but the output changes from kinetic to therapeutic. For the individual engineer, the career calculus is shifting toward the sector that has both funding and a use case validated by real pharma contracts.

The space workforce spent sixty years building vehicles. The next chapter is building what those vehicles carry, and that same production floor now feeds a spacecraft rather than a shipping dock.

Working in frontier tech? Zero G Talent tracks the openings: browse frontier tech jobs, openings at Varda Space and Axiom Space, and the people building the field.